Please provide your email address to receive an email when new articles are posted on . Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated ...

Ivosidenib is a targeted cancer drug. It is also known as Tibsovo. Azacitidine is a chemotherapy drug. It is also called Vidaza. You pronounce ivosidenib as i-voh-sih-deh-nib. And you pronounce ...

Ivosidenib, a first-in-class agent, is an oral, targeted, small-molecule inhibitor of mutant IDH1. The new approval was based on results of a single-arm trial that included 174 adult patients with ...

• Ivosidenib comes as a tablet that can be taken by mouth either with or without food. • Ivosidenib tablets should be taken at the same time each day as prescribed by the doctor. • Swallow ...

HOUSTON -- Progression-free survival (PFS) in IDH-mutant low-grade glioma remained twice as high in adults who received vorasidenib (Voranigo) after surgery versus placebo, according to a follow ...

Review the side-effects of Ivosidenib as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

About the PyramIDH Trial (NCT06465953) PyramIDH is a pivotal Phase 3, multicenter, open label, randomized clinical trial of TIBSOVO (ivosidenib tablets) monotherapy and azacitidine monotherapy in ...

Ivosidenib (Tibsovo) is available on the NHS. It is a possible treatment for locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with an IDH1 R132 mutation in adults after 1 or more ...

Ivosidenib (Tibsovo) with azacitidine is available on the NHS. It is a possible treatment for untreated acute myeloid leukaemia with an IDH1 R132 mutation in adults who cannot have standard intensive ...